JNCE - Earnings call transcript Q3 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

00:03 Good morning, ladies and gentlemen, and welcome to Jounce Therapeutics Third Quarter twenty twenty one Earnings Conference Call. At this time, all participant lines are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time.

As a reminder this conference is being recorded at the company’s request. 00:24 I will now turn the call over to your host, Eric Laub with Jounce Therapeutics. ahead. go Please

Eric Laub

release, issued release earnings topics The that outlines operator. Investor we you, our in available welcome Eric Vice twenty Laub, the XX:XX at the This Jounce to morning, Media which of today. one website twenty quarter Relations Therapeutics and section www.jouncetx.com. call. plan of discuss Therapeutics. the press President a This XX:XX is we Jounce Investors Thank & third is conference Good to morning at

Speaking be Dr. on progress CEO Richard our by Trehu, our Murray, milestones; on activities. pipeline update Beth our clinical key call our who today's will an and will CMO, Dr. who President, will and provide followed review

our Kim results. our discovery efforts. Our Dr. CFO, And Drapkin, quarter financial review discuss CFO, our third Dmitri Wiederschain, then will lastly, will

We Before open purposes that everyone statements XX:XX and expectations, for we to of your today's plans, begin, about discussion the will questions. of remind the in for XXXX. the like important under forward-looking include provisions forward-looking of Reform statements statements will future that would then the call our constitute I prospects Act by differ Actual a those results Securities our may as SEC result Litigation filings. Harbor the materially including these discussed Private factors, from Safe risk XX:XX factors indicated various

upon today, forward-looking In relied views our twenty representing fourth, November of one, as represents twenty date. addition, should of as statements be as any only any views and not our subsequent

so our change. I'll the specifically some to in elect call While that, the update at if now future, to we views do any to over we disclaim point With turn Rich. these statements forward-looking XX:XX obligation may even

Richard Murray

progress Good for a all today. and across morning has significant areas as quarter joining Eric. had us we the of you made Thanks, company. XX:XX very productive Jounce thank

progress progressing from XX:XX now clinical combination we to the candidates runway our year points. expansion or allows within targets cash reach INNATE We which distinct in inhibitor, momentum efforts, patients program and programs patient different cohorts are testing mechanisms to tumor expected two two from ongoing remain macrophage are our inflection build having select with pleased advance environment. in continue own our across and We're discovery stringent cell We twenty T studies, the twenty portion our a evident new which data and cells. into our selection to and regulatory that target monotherapy committed that study, head build time pipeline. to new our to to study, in eight immune as continued in employs enrollment development seven micro myeloid us continue pimivalimab, and of PD-X strategy that plus discovery types report JTX-XXXX, XX:XX we therapy licensed in minus to Jounce’s We recruiting new types. patient XX:XX our have new is our and actively commitment active exciting the the an This tumor now and Gilead,

cancer medicine precision to the At to not types, continued immunotherapy immune We efforts. of differentiates We translational biomarker monotherapy bring we this or through different approach LILRBX, in the is immuno-oncology execution of escalation but the only in as the also checkpoints all and The macrophage of with highest key and safety year, dose enrollment quickly XX:XX is INNATE. move us, clinical along and selection tested a as mission combination right believe right patients. cell therapy checkpoint through inhibitor Biomarker by Jounce represents our generation unlocking of targeting also beginning the to integral on next the XX:XX ILTX our comers, divisions. an therapy PD. for JTX-XXXX, program. announced had that a our necessary an known JTX-XXXX, priority commenced being pimivalimab monotherapy of XX:XX combinations study and

resistance While therapeutic and expansion allow bring expansion growing milligrams few provides tend across to cohorts, as resistant patients mechanism, patient have inhibitor forward especially well-defined to patients, patient recently and milestones populations We to seven by twenty with dose announced XX:XX macrophage mentioned, a population, this enrollment and twenty and new advance for further monotherapy our X two. we combination PD with to program, the in or JTX-XXXX tumors. in hundred seven first combo treatment. targeted We SELECT therapy types. continues tumor As representing the preliminary cohorts via for myeloid we the reaffirm determined XX:XX selection. study. dose enrollment XX:XX and PD-X presenting clinical PK this these biology to the the and anticipate to We for patients benefit in eight establishing primary the from and mono inhibitor options previously LILRBX delivering in safety Patient program acquired opportunity we due to to recommended PD-X that XX:XX prior data look belief Phase

and and to studies, mechanisms believe continuing fund Our novel to study Phase have Pimi. selection robust set in concept the selection trial We to clinical XX:XX while on the signature of of The concept X in data pleased a track an to candidate. months, We optimize is opened in two by XX:XX the in on In developed are twenty twenty Raythatha. remain of We with ICOS we vopratelimab and the are identifying We reporting efforts. critical agonist. on successfully cell years. our the developed a With our SELECT the that another INNATE Beth, reverse that strategy Agonist, over committed to clinical past others look Gilead. includes June, are to or CDX patient tumor Jounce biomarker to Jigar a two. experience strong T and maybe the data JTX-XXXX. to that nominate progressing to points the from the From microenvironment. new Jigar track of needs to key in to patients call discovery utilizing board twenty Before and within have rigorous CDX and the twenty eighteen of all the one. of position every In joined set the targeted five gene clinic synergistic types, efforts, randomized an cell is directors. feature was immune financial the our forward for discovery Jounce, skills our quarter our situated select our ended turning like genes with up new benefits I'd ICOS in of inflation wholly-owned pass announced their proof formerly we trial are eighteen to own study with back TISvopra, welcome GS-XXXX, combination extremely relevant work. to goal and relevant and His our candidates twelve proof fully for And biology. August, IND achieve and now of milestones XX:XX this September, highly from We initiated both XX:XX IND clinic internally clinical the XX:XX

to forward a an as now of update. member are intimate XX:XX to call science, we As I'll working a member. Board knowledge our team over of contributions Jigar a provide We has Beth? as of working to the understanding what clinical now look as achieve. Jounce, well to an continued Beth turn his former

Beth Trehu

I'm continued good we and clinical progress morning. Rich XX:XX both our made have execution trials. pleased in SELECT extremely with and the INNATE Thanks,

Unfortunately, improved options. Before proof in XX:XX our point based concept need getting IO I'd too ongoing patients the better patients studies, cell on to cancer T into of Rich from far therapies. still many detail there benefiting about of emphasize like not made are

patients and in immunosuppressive anti-tumor PD-X of two, dose treating unmet why is that XX:XX dose PD-X sensitive plus JTX-XXXX checkpoint XX:XX unmet oncology the such monotherapy macrophages immune bring naïve cohort Both a our an from Turning tumors. to parts. and We JTX-XXXX With comprehensive macrophage this monotherapy cell This for resistant the patients, the JTX-XXXX four clinical our are system, immune solid JTX-XXXX in solid state to immune LX macrophages to and bridge inhibitor tried to these escalation not are overcome create tumors. to Part JTX-XXXX inhibiting with benefit escalation ovarian arms all one tumors cannot JTX-XXXX belief Pimi and trials JTX-XXXX are aims Pimi and all as who address to consistent is as directed reminder, expansion identifying and three, XX:XX cancer. comers barrier and a to system. right bringing INNATE non-responsiveness. a priority plus tumor, key Part more consider immune goal greatest Part and Part resistance convert T and our optimally checkpoints alone the the mechanisms dose moved checkpoint in benefit to in populations might do. comers in cells with the INNATE By patients INNATE we that first our or that need study. PD-X in efforts the clinical and As seven four treatments that improve of one, potential about team innate to they significant of the enthusiastic of novel inhibitors. strategies and response planned, this. tumors. the tumor proud SELECT we are to can in T-cells specific the program. be believe expansion effective something in mean highest with targeting substantial or do INNATE T-cells accomplish is our need necessary and we inhibitors. the to cohorts. the the be of patients the the between to is immunotherapy study, and are INNATE mind JTX-XXXX, outcomes inhibitor As has new of For biomarker XX:XX XX:XX quickly T-cell PD-X we of divided right patients potential trial both to a through patients, bring made escalation resistant inhibitor the

important the With subsets and both paths will PD-X concept steady in The completed, JTX-XXXX or the most cohorts of are in cohorts. alone of identify escalation of monotherapy we rapid dose patients board inhibitors. enrolling INNATE and to combination in the patients the proof three for expansion with expansion XX:XX in portion of development combo JTX-XXXX now order combination mono

sarcoma. and These repeat cancer, targeted for cell few First, breast carcinoma, lung this which options respond on renal a and Indications, an patient unmet cell don't need squamous progress population immunotherapy cancer impact. we immunotherapies largely high area have PD-X this typically have This cancer, to Indications had cell patients unsuccessful. of directed triple XX:XX naïve cell PD-X inhibitor PD-X clear population, patients in resistant. significant very inhibitors. that patients inhibitors for ovarian have with has have treatment includes and cutaneous we carcinoma, tumors include T-cell who is Second, and been also patient inhibitor not targeted XX:XX negative are non-small PD-X now

approved, we have of naïve PD-X interest areas squamous and microenvironment improvement. cell multiple carcinoma. for for approach to room still patients for indication JTX-XXXX, neck with this frontline for Finally, inhibitor targeted the patient inhibitors across analyses Earlier XX:XX tumors translational of environment population disease year, tumor shared but head PD-X this tumor are is The on there defining we types. our based which

differentiation Jounce’s these exciting the or taken developing assignments up two and the need, if is nine to of potential We pre-specified biology, and will Proof and cohort, cohorts the mentioned disease enroll PD-X expansion XX:XX resistance. specific important XX:XX cohorts distinct assess to and pharmacodynamic concept previously. criteria monotherapy in to competitive indications sensitivity three patients. interest are the inhibitor have LX of forty twenty it to biomarkers this combination follow of and to of and populations with INNATE INNATE to for aligning future met. the right areas with immunotherapies in development, stage seven stage based expansion We defined patient patients potential for right new on mechanism the predictive investigate in believe patients design include of unmet consideration guide INNATE also in at up philosophy

JTX-XXXX expansion other INNATE explore registration. indications combination Jounce cohorts we the as data combinations molecules, and the JTX-XXXX potentially take Importantly, two in with to us will emerges, and to have to well. As allow Pimi XX:XX opportunity through

approximately expected biomarker XX:XX in who We genes date Pimi Pimi Vopra and on to naïve of randomized eighteen with of lung rigorous well. validate cell X enrollment our guide is screening and SELECT combination an we Phase screening study line Vopra, to turning The predictive percent as patients immunotherapy Now, represent will gene our patients, this this to of well continue biomarker from PD-X of of precision release is cell own cells. Pimi these CDX the essential as selected non-small Vopra inhibitor will data. concept trial plan We both cancer second includes a vopratelimab of could to seventy pharmacodynamic via a of twenty utilizing PD-X approximately we effect were cells, in non-small to approach year, to be Next and projection. this positive to how the using alone. that vopra in XX:XX progress predictive be IO. five randomized proof Difficulty] biomarker the feature cancer inhibitor via plus medicine lung [Technical TIS selection and TIS versus response believe patients when TISvopra signature SELECT unique continues XX:XX

thank to like track the patients our to We in share progressing would team the with at to and privilege how two. are take who have twenty data treat. on is twenty to moment I are our Jounce, we a investigators, pleased enrollment and

look Dmitri year believe this our is approach immune of over With this to cells, long-lasting Now, more upcoming next ongoing our turn imperative commitment and benefit and targeting to call us progress to science that our delivering achieving important mechanisms continued I We became execute translational discuss than to our to new brings now ever, XX:XX I it delivering forward Dmitri? the target. Our biomarker on closer discovery cancer that, to milestones. efforts. will on we different patients. mission XX:XX to

Dmitri Wiederschain

Beth. Thanks XX:XX

generating address that the may lead that us problems checkpoint using with cell immuno-oncology example our cell targets to checkpoint to improve the tumor will XX:XX believe family to key and the XX:XX patients from LILRB biomarker of are an our to to inhibitor be integrated time through the JTX-XXXX or today. facing inhibitors. of important overcoming T We confident We resistance molecular for blockade. platform are responsiveness approach target are that at ability translational value specific to attractive discovery is upon that the Namely, we utilization development. pursuing. PD-X We resistance are XX:XX cancer gene a the to approach the level on restore to with focused therapy. immune LX macro serves as signatures type potential dissect environment This represents our programs

discovery, LILRBX. two one LILRBX As additional LILRB disclosed programs earlier other rapidly this and are family year, the advancing we targeting targeting through

candidate we discovery to that to are track on are We value development we're exploring highly specific LILRB leveraging have the and family. nominate LILRB addition, our Today, XX:XX our building In now next been very within targeting blocks successful efforts biologics generate preclinically. generating. multi-targeted

scientists to in and to commitment steadfast in novel research teams bring their patients broader Our need. therapies are

turn for XX:XX on quarter work over updates look now Kim? and third very our in are their Kim proud I will our I to discovery financial discussion productive We of of sharing the future. forward the results. engine Drapkin call to a

Kim Drapkin

Thank XX:XX Dmitri. you,

of a to thirty, quarter from recognition revenue one third and twenty includes twenty one twenty December million increased thirteen and and twenty XX:XX Turning balance September or The forty third dollars the thirty, dollars quarter. million release, September the compared milestone nine twenty. in press two equivalents twenty five Gilead during in received twenty one two no twenty cash point As hundred cash, of two the as investments to million recognized dollars was the one, we as L, this twenty P of cash reported twenty. morning's thirty twenty

for to our on share We was expenses XX:XX the is and twenty thirty same decreased of and a per an twenty eighteen twenty same four million period During twenty three the basic twenty period capital for share performed approximately payroll in was XX:XX for the development and dollars. compared incurred attributable million as dollars nine year seven same operating one the three nine third manufacturing one net quarter a increased Net million a of five research million attributable of the clinical in and periods the increases development expenses. cash a twenty administrative period point of for result decrease compensation one loss loss net million hundred twenty million dollars dollars activities twenty the in of per one twenty. our expenses increased for one quarter professional decrease compared were million of expenses expenses expenses twenty and hundred net XX:XX twenty the XX:XX and loss burn two based to The point G twenty twenty one, is loss we number third offset quarter dollars twenty A one of in third dollars expect in point expenses loss point dollars basic in point twenty. per dollars due be primarily resulting six guidance zero in INNATE other expenditures loss twenty one, operating to ten stock were R and programs as The approximately and resulting SELECT, in twenty, and compared to three regulatory in and increased to for administrative and shares of diluted to outstanding million dollars, and zero to in in twenty in D seven General twenty and to full narrowing nine increased increase dollars increase cash for dollars. million diluted fees, for one twenty expenses twenty. costs. The net growth same the compared net ending and point are by burn with point share

funding investments final some now XX:XX through enable hand the of expenses and equivalents, our to our quarter operating the and twenty Richard, to sufficient third capital words. expect requirements I'll cash, twenty three. be cash We of expenditure existing to

Richard Murray

medical every XX:XX made IO experienced position science, team growing out unmet and proud to of congratulate our we of advances pipeline continues Thanks, to the a faced efforts innovative and in continue address Kim. like to Before execute the and cancer and take pipeline. combination recognize XX:XX moment fourth them set patients to puts inflection IND net of first to need financial we're to on makes building I'd plans. we're A move team, and resources points, our our the the our Jounce strategic strong our a by closing, all beyond across focus us on day our patients.

dedicated partners fortunate having mission. that such our investigators collaborators and we’re in Additionally, clinical are true in

We exciting forward have we'd look important you the on year Operator? with call upcoming data and to we progress. an now open like updating clinical XX:XX With questions. expected, for your our to that,

Operator

XX:XX question Thank Our with you. [Operator line first Tenthoff Ted the Instructions] from Sandler. of comes Piper

Your now line open. is

Ted Tenthoff

you XX:XX the much Great. update. and Thank very appreciate

sense So INNATE appreciating much expectations timing for ICOS year, you on I combo? sort ask PD-X just a for question get see as the what next going SELECT to around potential be Thanks. and data could on steps my there next [indiscernible] of what and and wanted and

Beth Trehu

Beth. XX:XX Thanks, is Ted. This

from data our We trial XX:XX but be So, that all need Phase And was the we've said, a study be recall, concept, of we X next the to the and combo study arm. will our to SELECT and give year information our for intention the the this designed and secondary study endpoint this will if endpoints as all on will supports is the you both data design a follow proof study, have may alone believe for the of I be registration that. registration. final one generate this reiterate, the randomized to with Pimi it as we'll Pimi primary we that study next data data,

Ted Tenthoff

be pursue you early will loan? dependent, do opportunities it’s combination again, obviously see but data and to this it XX:XX to, And beyond

Beth Trehu

Yes. XX:XX

in informative twenty room something Remember, other one IO across biomarker with as there's improvement is cell found targeting combination TIS the Vopra used, that and we'll broadly are agent. belief could applied and of selection the tumor for we of general for XX:XX types. in are T the percent from where this but very plus inhibitors Select, other and addition Vopra type can is better types, patients believe with positive types tumor tumor be Pimi Our CDX the be that PD-X data about that agents plus across of be we looking patient tumor

percent, that of have We well, on as of we're to data biomarker of therapy. from percent as selection top to some this who some benefit eliminates the honing those most benefit likely really opposed twenty like which in targeting but the are who percentage really PDL-X, in we're most prevalence kind other think the I on are patient patients the twenty exciting likely to that's bottom

Ted Tenthoff

the further add combination focus and ball down then that you all I of so field, XX:XX potential checkpoint And is moment, the on evaluate but take therapy? guys mechanisms time moving this [indiscernible] much Yeah. are readout, to [indiscernible] sense to the inhibitors? this data and is know this mechanism there SELECT data the SELECT for and before for one already might one, as other but that's make even there to a other kind and triple

Beth Trehu

XX:XX Ted. Yeah, question, a great that's

I iconic has question in Vopra inhibitors. shown answer and add of the does of to the with is plus Vopra been, to think and with we've checkpoint not trial even the Nivo first the any Vopra of the as part safety [indiscernible], Pimi combination Vopra toxicity that

those the So together. consider with adding same and for that very goes additional combinations up with science And be any that two taking combinations do, we everything new opens very, possibility any may as we drugs certainly driven additional for drugs the JTX-XXXX. would

Richard Murray

to the just yeah, question we very I And, environment think a comment, different is the of lead logical also all much in think cell types combinations. that think the for really part tumor XX:XX that

know cell will biology the type the combinations. that the you to up think kind going on we macrophages cells, to that we to and lead continue T best specific of PD-X we’re So, push

Ted Tenthoff

sense. of XX:XX lot the a Makes for Thanks all time.

Operator

of Boris from XX:XX Peaker line with Our question next comes the Cowen.

now Your open. line is

Boris Peaker

recommended you eighty see curious X did establish dose or dose? did the first you a how sixty Great. Phase is XX:XX on response four. I'm just My question

Beth Trehu

XX:XX Sure.

So, antibody. inhibitory a monoclonal classic this is

dose continued based and X occupancy the Phase recommended the is so, or receptor dose that we're using development on And for PK.

patients we're And XX:XX of full have from wanted three We able data both occupancy three actually so, based determine receptor full percentage the have be receptor the peripheral receptor which given was week taking different the safety. see is PK any not potential inter receptor occupancy forward, So, would weeks, but we you clinical the receptor from of full differences choice every amount assays dose in both blood. course, will milligrams, the occupancy patient of may data to occupancy PK who using and at of occupancy, to hundred and really seven at entire tumors, through also which those saw dose the optimize and on we're cycle. the that and other the the of what patients requisite than milligrams in hundred dosing data the optimize XX:XX three

Boris Peaker

it. Got XX:XX

the market? just study, how I'm can can for us we scale select remind from a clinical TIS how again maybe Okay. the scale the and commercial biomarker you thinking, on And up works to specifically scale

Beth Trehu

XX:XX Sure.

physicians. currently this is signature. and XX time question is, effort that make the to you have patients also and we're RNA a an lot a use done that spending gene something So, platform, important commercial NanoString it's and for make on something and a very but scalable asked it's It's easier how for it on of

companion widespread it's take add you believe the to that that's you we diagnostic. platform so, in Rich? NanoString feasible very and is Do but that's this works, forward anything something to want but know, as So pretty a

Richard Murray

clinical Boris, that's of XX:XX accordingly kind all Yes, in I with think data. dated the pace

forward, it step as clinic the into the step that now, moving using would the of to with be really of next to how in take kind that realm that next So, the use commercial biomarker. clinical then we're next, coordinated more

Boris Peaker

taking questions. Great. for my Thank XX:XX you

Beth Trehu

XX:XX Welcome.

Operator

question the Seedhouse from line Steven of James. with next Our XX:XX comes Raymond

now open. Your line is

Steven Seedhouse

morning. Good Thank you. XX:XX

wanted that hypotheses your I data published, any you share you contradicts before paper, mechanism? supports know at just your data inhibitor on if Phase the Merck you the and cohort know regarding that As closely look what could guys expansion but or I to of or was the ask your either Thanks. in X for thoughts paper recently choices

Beth Trehu

XX:XX Steve. Thanks,

saw by about those We're I PD-X in that biology and data really of the particular very inhibitor just think resistance mechanism. this who the beyond is has our approach. reverse the this think the that We very and I who say supportive following benefit general, the be the in PD-X to of if biomarker? we completely respond they've able that about is exploring they're published patients something in increase it's super paper, to recent tumor to encouraged the following. number remain can shared, to inhibitors. identical biology excited Dmitri, they're types think you to we is believe want the it kind of data that Merck mechanism of data that I we're not similar really the published. they And that in And data were XX:XX may pleased see to their a continues terms reinforce that

Dmitri Wiederschain

XX:XX Yeah. Thanks Beth.

I Merck largely Publication is our [indiscernible]. think around with consistent hypothesis as mentioned Beth

our during [indiscernible] and and few a market in D As ago, CD-XXX is it months and a R disclosed cancers. a many market prognostic negative day mentioned we is

we tumor I Merck think the that’s could interferon ratio inflammation, very specifically messaging also is LILRBX of to negative the the a which signature, of be many the consistent [indiscernible]. predictor again, opportunities gamma biomarker to with inhibitors biomarkers. [ph]. was where XX:XX We're INNATE analyzing to show] and assess have forward think that's [biomarker from to response shown very data in we've that looking And predictive what PD-X potential consistent I

as relationship them efficacy. as correlate at individually, each be that with well clinical other the to will We looking and

Beth Trehu

those and with that mentioned just we I'll and data Maybe expansion Yes. XX:XX clinical cohorts biomarker we data. INNATE, will biomarker pharmacodynamic when potential predictive have data the report from do the the included

Steven Seedhouse

you. Thank Great. XX:XX

Operator

J.P. question comes with Cory from Our of Morgan. Kasimov XX:XX next line the

Your is now line open.

Unidentified Analyst

This XX:XX for Cory. Hi Thanks question. for is the guys. Tiffany on

Just board? cohorts one enrolling across gone across are faster cohorts on INNATE, how pretty your others or has trial similar than the expansion enrollment certain

Beth Trehu

question. XX:XX Thanks we're the pleased enrollment. for with Yes, very

rates enrollment assumptions different based on into have and and our the our prevalence type selection those we to tumor cohort all of each site expected We of program timelines. built the

now, of as So, things well. are going

Operator

line Baird. XX:XX Colleen the next comes question Our Kusy from of with

is now open. line Your

Colleen Kusy

Thanks questions. Great. for our taking XX:XX

the hundred why four, higher INNATE eighty at On exploring of study, you a you've be potentially said, the for higher that any dose a on you and dose seven I beyond might be previously think looking sixty dose update mix? would

Beth Trehu

Thanks, both dose is completed completed hundred Colleen. doing We've purpose the dose milligrams we've the was really for was three planned the forward that, profile us We've XX:XX twelve time, to the taking dose the monotherapy to And the just that that. test. to we're So, with that higher we In expansion in happy cohorts. drug seven but highest dose went escalation, XX:XX of that's than chosen we've take a up milligrams of this escalation at weeks. twelve we hundred forward, every it and our completed very one safe. safety to hundred that the that combination, information dose give at about we're

Colleen Kusy

dose XX:XX that the you're you. dose using INNATE study, on and Pimi remind for doses still to compares that what using then the And the Got helpful. the the Thank it. SELECT study? how for That's in us you're

Beth Trehu

is the weeks, Pimi doses five every weeks, every had different since milligram three of a JTX-XXXX dose the, either hundred six using Pimi The is every or three dose. recommended was we're we two which thousand milligrams Phase three given hundred every two And five Sure. weeks weeks. XX:XX hundred for five

Colleen Kusy

Thank that would XX:XX the INNATE dose for question Got next – early And that update do would you last it. escalation that year, and expect include data? expansion dose both then you.

Beth Trehu

Correct. Correct. XX:XX

this to is presentation really goal of data Our have possible. meaningful as a

cohorts from include data and least on the of the data expansion would all escalation patients pharmacodynamic at biomarker and data, that of with eighteen predictive preliminary weeks so, also dose And the data.

Colleen Kusy

taking for Thanks Great. XX:XX the questions.

Operator

Instructions] from line question [Operator Capital Our of XX:XX with next comes the Partners. Zegbeh Jallah Roth

Your line is open. now

Zegbeh Jallah

XX:XX I just have Hi. Thanks taking two for my quick ones. question.

about competitiveness and is curious folks study, the that combo those in a get and sense And of the one know, arms been first you've one getting The a to the efficacy we’ve about still just just wanted on of think inhibitor. is the the PD-X the INNATE arms your questions gone this, of but about data I about different safety. key lot through are

and can competitive then PD-X? thinking to comment just is you are other So, that about you on relative how

Beth Trehu

of other Pimi response patients Phase that importantly, was So, quite in no PD-X similar had not a all inhibitor was of and Pimi. as toxicities you to to neck a every because use We to very by the definition the cancer. Pimi had comers that XX:XX escalation know, dose pleased have and a in inhibitors, very all naïve failed we're and expansion the INNATE PD-X XX:XX were cohorts, able that inhibitors trial. So, had therapy. and PD-X we're using trial, studied we in could doses head tumors SELECT safety the And with have we're including X both seventeen we in percent very efficacy to trial and it frontline available dose-limiting – and pleased originally had rate

from own wholly-owned at a inhibitor for but So, the PD-X trial, able perspective drugs big and us two gives get to the also clinical use and both potential it's flexibility a approved to end. cost perspective advantage it to us the doing actually our be for

Zegbeh Jallah

a know XX:XX is It's strategy Thanks biomarker back last Beth. you one novel all a as view year. the And it of this lot signs still about mentioned, just as good there's still but of exciting. very a and in model you SELECT, call then option, just you

or approach recently you to this there's stronger readout? data more what and else of so, that a anything folks seen on about bit in if done are this the terms internally comment this a conviction uniqueness bit around And recently the you're for interesting, give you understanding just program more can you've program, that and more about thinking outlook you've little of of that

Richard Murray

Zegbeh. could Yeah. XX:XX take I one that

the think data. that thing important biomarker TISvopra, I most is in the describing that clinical from we're learning applying, we're

following us, the those the small know pick rigorous analysis. think for the really but case, really to of follows of puts of it us being an been one So, I for retrospectively so, patients. currently of position of of us. immunotherapy is most biomarker, that the the the the one the bring cases So, where to from is, there that a and removing And right cut a and we the the been and kind in It's XX:XX clinical oncology. in stringent of that a logic show think up hasn't to that data right identify we percentage the we retrospective XX:XX really has date, biomarker that's immunotherapy this observed, you patients, of to example for of selection us, following lines of medicine precision driver really this more really benefit science, selections. Where approach patients point was can follow kind out can kind able clinical

So, driven data. our by clinical and it’s taken, that’s science

Zegbeh Jallah

Richard. XX:XX Thanks

quick a Just follow-up.

I know key set. be would think, this that's you been the to threshold

if wondering not just around comment your threshold biomarker? or conviction did the you for again whether just on was you right I so, select And your can

Beth Trehu

on, to gives but being really patients of sensitivity one actually generated are thresholds Doctors And eligible on Rich From also a a to us seems from be a and in trial to Yeah. finding can twenty five based that, have So, TISvopra patients they all SELECT to patients finding and – tough most XX:XX this really is percent practical four lot is likely that's patients talking think manageable. XX:XX the have continued pleased than that sensitivity percent the – of we've retrospectively, have of has specificity. of it that data really percent the which being we screening extremely spot willing the was from as clinically the group the but this point, we benefit, positive, of seems knowing challenging. in XX:XX better patients biomarker be that to screening best been the twenty do that really biomarker. the data a best about finding way chance

very up So, well. it's worked

Zegbeh Jallah

as XX:XX the Thanks of side to bigger in trying Beth, heard market. likely of really of caution most a appreciate. part And that the I get you patients picking terms guys opposed think to to folks glad on to respond know

Beth Trehu

Yeah. XX:XX

Operator

you. XX:XX Thank

comes Swayampakula question of the last line from Our Ramakanth with H.C. Wainwright.

Your line is now open.

Swayampakula Ramakanth

till morning, and that twenty but are twenty expansion two, have to With Rich Good be you. data or wait release? combination want in the you the to to indications, Thank would try studies been of different available my you going – especially on would releases Beth. how eight wise initiated? are towards in all work different to in data want Most going recently cohort the asked, understand the cohorts cohorts questions XX:XX to you these from cohorts, just of releasing seven data all the

Beth Trehu

Yeah. XX:XX

think a and of that data body across to said cohorts. is goal present means multiple meaningful data as Our we I

what it data data. along Yes, that's can you across expect So cohorts. biomarker will be And multiple with

Swayampakula Ramakanth

therapy, way will good to you a XX:XX to to would you're plan at how trying both study you fronts, late Fantastic. you if let's on ovarian therapy? I'm cancer a And rationalize, monotherapy stage combination which looking I'm trying say data is just a both the to just do figure out go, as things? and both combination these as monotherapy or how sequence understand, and

Beth Trehu

if most fastest all because path expect XX:XX question. likely of combinations. as also The with is sufficient Sure. to this a support that's to for data that registration, for always there It there, a is to but of in That's proof the is concept, could a cohort important we monotherapy immunotherapy helpful used us was be have Eventually, monotherapy. good market.

So, in gets look of development but greatest the number the will possible also the approval serves do the way data and we'll that us JTX-XXXX, a early at for patients.

the really as be determined look will it So, at data. we

Swayampakula Ramakanth

Rich. Thank you. Thank you to Beth. you, Thanks, Talk XX:XX soon.

Richard Murray

Sure. XX:XX

Beth Trehu

XX:XX you. Thank

Operator

are and There Thank you no for your this conference call. Ladies concludes participation. you. questions. today's Thank gentlemen, further XX:XX

You disconnect. may now

Jounce Therapeutics (JNCE) 4 Nov 212021 Q3 Earnings call transcript